USS Investment Management Ltd Has $7.67 Million Holdings in argenx SE (NASDAQ:ARGX)

USS Investment Management Ltd trimmed its stake in argenx SE (NASDAQ:ARGX) by 14.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,463 shares of the company’s stock after selling 2,136 shares during the period. USS Investment Management Ltd’s holdings in argenx were worth $7,673,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ARGX. Voloridge Investment Management LLC bought a new stake in shares of argenx in the 4th quarter valued at about $28,510,000. Woodline Partners LP lifted its stake in shares of argenx by 299.5% in the fourth quarter. Woodline Partners LP now owns 74,237 shares of the company’s stock worth $45,656,000 after acquiring an additional 55,656 shares during the period. Vident Advisory LLC boosted its holdings in argenx by 7.5% in the fourth quarter. Vident Advisory LLC now owns 890 shares of the company’s stock valued at $547,000 after acquiring an additional 62 shares during the last quarter. Squarepoint Ops LLC increased its position in argenx by 24.5% during the 4th quarter. Squarepoint Ops LLC now owns 22,664 shares of the company’s stock valued at $13,938,000 after purchasing an additional 4,464 shares during the period. Finally, Tema Etfs LLC bought a new position in argenx during the 4th quarter worth approximately $2,828,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ARGX. Wedbush reiterated an “outperform” rating and set a $715.00 price objective on shares of argenx in a research report on Friday, April 11th. Robert W. Baird upgraded argenx from a “neutral” rating to an “outperform” rating and set a $680.00 price target for the company in a report on Tuesday, May 13th. William Blair reissued an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Oppenheimer raised their target price on argenx from $704.00 to $708.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Finally, Wells Fargo & Company lifted their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $698.11.

argenx Price Performance

Shares of NASDAQ ARGX opened at $584.95 on Thursday. The company has a 50-day moving average price of $590.90 and a 200-day moving average price of $612.98. The stock has a market capitalization of $35.72 billion, a P/E ratio of -664.72 and a beta of 0.57. argenx SE has a 1 year low of $358.80 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.